Phase 3 cancer immunotherapy company Cel-Sci (NYSE:CVM) announced today that it raised approximately $10 million through the exercise of warrants. The Vienna, Va.-based company plans to use the funds to complete the expansion of its Multikine cancer immunotherapy manufacturing facility near Baltimore in anticipation of a biologics license application (BLA) submission and the subsequent effort to receive […]
cel-sci
CEL-SCI prices $5.5m common stock offering
Phase 3 cancer immunotherapy company Cel-Sci (NYSE:CVM) announced today that it priced an underwritten public offering of common stock with expected gross proceeds of $5.5 million. Vienna, Va.–based Cel-Sci is offering 606, 395 shares of common stock at a price of $9.07 per share to total the $5.5 million before deducting underwriting discounts and other estimated […]
CEL-SCI wins $2.9M in CRO legal battle
Score one for the little guy. After a four-year legal battle, immunotherapy maker CEL-SCI Corporation has won the first-ever breach-of-contract case against a contract research organization, or CRO. In a final and binding decision, an arbitrator concluded that CRO inVentiv knowingly and fraudulently misled CEL-SCI with regard to enrollment projections for a clinical trial of […]
Cel-Sci raises $3.5m for head and neck cancer immunotherapy
Cel-Sci (NYSE:CVM) said today that it inked an agreement with institutional investors for a $3.5 million registered direct offering. The company said it plans to offer 1.75 million shares of common stock at $2.00 apiece. In a private placement, Cel-Sci will issue warrants to buy up to 1.75 million shares of common stock. For each share of stock purchased […]